| Bioactivity | Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research[1][2]. | ||||||||||||
| Invitro | Indacaterol (1, 2.5, 5, 10 µM; 12 h) inhibits TNF-α induced MMP-9 expression and activity in human fibrosarcoma HT1080 cells[1].Indacaterol (10 µM; 6 h) inhibits TNF-α induced invasion and migration of human fibrosarcoma cells by reducing MMP-9 expression and activity[1].Indacaterol (1, 2.5, 5, 10 µM; 2.5 h) inhibits TNF-α-activated IKK/NF-кB signaling in HT1080 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | Indacaterol (0.3 mg/kg; in animal drinking water; sinle daily for 15 weeks) shows activity of normalizing and reversing cardiac remodeling in a myocardial infarction (MI) rat model of heart failure (HF)[2]. Animal Model: | ||||||||||||
| Name | Indacaterol | ||||||||||||
| CAS | 312753-06-3 | ||||||||||||
| Formula | C24H28N2O3 | ||||||||||||
| Molar Mass | 392.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37(8):585-91. [2]. Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015. |
Indacaterol
CAS: 312753-06-3 F: C24H28N2O3 W: 392.49
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.